Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/28/2026, 12:00:00 AM
AbbVie submitted an sNDA to the FDA for upadacitinib for the treatment of alopecia areata on 2026-04-28; this potential new indication is estimated to have a ~5% positive price impact expected.
Korean Translation
애브비는 2026년 4월 28일 원형 탈모증 치료를 위한 유파다시티닙의 추가 신약 허가 신청(sNDA)을 제출함. 신규 적응증 확대로 인해 약 5%의 주가 상승이 예상됨.
Related Recent Events
Bristol-Myers Squibb Co (BMY) · Other
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026, for its decision on iberdomide for relapsed or refractory multiple myeloma, scheduled. Low impact estimated as the target date is a procedural milestone.
8/17/2026, 12:00:00 AM
Blackstone Inc (BX) · Earnings Release
Blackstone is scheduled to release its Q2 2026 earnings results, with analysts forecasting earnings of approximately $1.34-$1.36 per share, scheduled.
7/23/2026, 12:00:00 AM
Union Pacific Corp (UNP) · Earnings Release
Q2 2026 earnings release is scheduled. Low impact estimated as the date announcement is a routine event; scheduled.
7/23/2026, 12:00:00 AM
Goldman Sachs Group Inc (The) (GS) · Earnings Release
Goldman Sachs' Q2 2026 earnings release is scheduled.
7/14/2026, 12:00:00 AM
NIKE Inc (NKE) · Earnings Release
Q4 Fiscal Year 2026 earnings release is scheduled for June 25, 2026. Low importance as the announcement of the date typically has a minimal market impact.
6/25/2026, 12:00:00 AM
Vistra Corp (VST) · Other
Quarterly dividend of $0.2290 per share with an ex-dividend date of June 22, 2026; low importance estimated as dividends usually cause minor price adjustments, scheduled.
6/22/2026, 12:00:00 AM